Alkem Laboratories Gopal Kothari as Chief appointed
Alkem Laboratories (ALKEM) said Gopal Kothari as Chief has been appointed. The company is valued at about ₹62,825 crore.
What happened
Alkem Laboratories (ALKEM) told the exchanges on 12 November 2026 at 01:58 PM that Gopal Kothari as Chief has been appointed.
From the filing: "Alkem Laboratories Limited has informed the Exchange regarding Appointment of Mr Gopal Kothari as Chief Financial Officer of the Company w.e.f."
Company snapshot
Alkem Laboratories is a mid-cap company in the Healthcare sector, with a market value of about ₹62,825 crore.
The stock last traded at ₹5,254.5, against a 52-week range of ₹4,811–₹5,933.5 (11.4% below the high).
Before this filing the shares had moved +2.3% over the month and −2.3% over three months. Average daily turnover over the last 20 sessions was about ₹50.7 crore.
Promoters held 49.70% at the end of Q1 FY27, down 1.50% points from the previous quarter. Foreign institutions owned 10.42% and domestic institutions 22.63%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,371 | 664.3 | 55.56 |
| Q2 FY26 | 4,001 | 765.1 | 63.99 |
| Q3 FY26 | 3,737 | 636 | 53.19 |
| Q4 FY26 | 3,603 | 236.5 | 19.77 |
| Q1 FY27 | 3,740 | 520 | 43.49 |
What history shows
BCEIE's records show 9 previous management change filings from the company since May 2026.
After those filings, the stock gained 0.3% on average the next trading day and was down 0.5% on average after five days (8 filings with price data).
Across 136 similar disclosures by other Healthcare companies, shares moved +1.2% on average the next day and +1.9% over five days; 51% of them rose the next day.
Market-wide, 4,506 management change filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 45% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 5 Nov 2026 | With reference to your email regarding the captioned corporate… | +2.2% | — |
| 3 Nov 2026 | We wish to inform you that M/s. Alkem Laboratories Limited has… | +1.2% | — |
| 12 Oct 2026 | Herewith intimation for appointment of Mr. Laxmikant Tiwari and Mr.… | −0.1% | — |
| 24 Sept 2026 | Resignation of Director/KMP/SMP | −2.6% | — |
| 24 Sept 2026 | Change in Key Managerial Personnel Resignation of Chief Financial… | −2.6% | — |
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 12 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alkem names former Zydus executive Dr Amrut Naik new CEO
- ALKEM Outlook for the Week
- Earnings To Watch: Alkem Laboratories Ltd (NSE:ALKEM) Q2 2027 -- GF Value Sees 32% Upside
- Bipin Lokegaonkar Joins Alkem Laboratories as Chief Information Security Officer
- Tech Query: Alkem Laboratories, Intellect Design Arena, Trent, SRF — What is the outlook? Where are these stocks headed?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.